Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung CancerMiguel García-Pardo, Natasha B. Leighl, Tracy Stockley et al.|JAMA Network Open|2023Cited by 60
Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer ConsortiumMiguel García-Pardo, Geoffrey Liu, Amy Chang et al.|Journal of Thoracic Oncology|2022Cited by 26
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung CancerSabine Schmid, Geoffrey Liu, Sierra Cheng et al.|Clinical Lung Cancer|2022Cited by 23
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and EfficacySally C. M. Lau, Adrian G. Sacher, Malcolm Ryan et al.|JTO Clinical and Research Reports|2021Cited by 11
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Geoffrey Liu, Miguel García-Pardo et al.|Lung Cancer|2022Cited by 11